Johnson & Johnson, ViaCyte testing possible diabetes cure

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

UNDATED (AP) — Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could cure the life-threatening hormonal disorder.

They’ve already begun testing it in a small number of diabetic patients, a first. If it works as well in patients as it has in animals, it would amount to a cure, ending the need for frequent insulin injections and blood sugar testing.

The companies have agreed to combine patents covering their research under ViaCyte.

Their therapy involves inducing embryonic stem cells to turn into insulin-producing cells while inside a small capsule that is implanted under the skin. The capsule protects the cells from the immune system, which otherwise would attack them as invaders.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s